Cargando…

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers

PURPOSE: Until now, results evaluating the expression of PSMA in ovarian cancer were sparse and contradictory. The aim was to reinvestigate the feasibility of a PSMA targeted theranostic approach in epithelial ovarian cancers with data from the tumour bank of a referring cancer centre. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aide, Nicolas, Poulain, Laurent, Elie, Nicolas, Briand, Mélanie, Giffard, Florence, Blanc-Fournier, Cécile, Joly, Florence, Lasnon, Charline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873152/ https://www.ncbi.nlm.nih.gov/pubmed/33559764 http://dx.doi.org/10.1186/s13550-021-00756-z

Ejemplares similares

Hormonal Receptor Immunochemistry Heterogeneity and (18)F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers
por: Aide, Nicolas, et al.
Publicado: (2021)

Quantifying and correcting for tail vein extravasation in small animal PET scans in cancer research: is there an impact on therapy assessment?
por: Lasnon, Charline, et al.
Publicado: (2015)

Implications of reconstruction protocol for histo-biological characterisation of breast cancers using FDG-PET radiomics
por: Aide, Nicolas, et al.
Publicado: (2018)

Impact of automated methods for quantitative evaluation of immunostaining: Towards digital pathology
por: Elie, Nicolas, et al.
Publicado: (2022)

Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4–2008 image quality parameters
por: Lasnon, Charline, et al.
Publicado: (2013)

Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic (18) F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients
por: Aide, Nicolas, et al.
Publicado: (2022)

Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors
por: Dolivet, Enora, et al.
Publicado: (2023)

Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-Bclx(L) strategies through Mcl-1 down-regulation
por: Bonnefond, Marie-Laure, et al.
Publicado: (2018)

Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs)
por: Lasnon, Charline, et al.
Publicado: (2017)

PET imaging and quantification of small animals using a clinical SiPM-based camera
por: Desmonts, Cédric, et al.
Publicado: (2023)

Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma
por: Aide, Nicolas, et al.
Publicado: (2017)

Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route
por: Meryet-Figuière, Matthieu, et al.
Publicado: (2017)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma
por: Thorel, Lucie, et al.
Publicado: (2023)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

Comprehensive analysis of the influence of G-CSF on the biodistribution of (18)F-FDG in lymphoma patients: insights for PET/CT scheduling
por: Oliveira, Magno, et al.
Publicado: (2019)

EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
por: Aide, Nicolas, et al.
Publicado: (2017)

Diagnostic value of baseline (18)FDG PET/CT skeletal textural features in follicular lymphoma
por: Faudemer, Julie, et al.
Publicado: (2021)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients
por: Lasnon, Charline, et al.
Publicado: (2013)

Assessment of alteration in liver (18)F–FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score
por: Salomon, Thibault, et al.
Publicado: (2017)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

PSMA Theranostics: Current Landscape and Future Outlook
por: Zhang, Hanbo, et al.
Publicado: (2021)

Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-x(L) inhibitors on human ovarian carcinoma cells
por: Lincet, Hubert, et al.
Publicado: (2013)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological (18)F-FDG anal uptake
por: Aide, Nicolas, et al.
Publicado: (2020)

(18)F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital
por: Le Goubey, Jean-Baptiste, et al.
Publicado: (2021)

Sensitization of ovarian carcinoma cells to Bcl-x(L)-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family
por: Tomasina, Julie, et al.
Publicado: (2013)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
por: Schollhammer, Romain, et al.
Publicado: (2023)

Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted
por: Benusiglio, Patrick R., et al.
Publicado: (2018)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
por: Gauthé, Mathieu, et al.
Publicado: (2021)

Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-x(L) strategies through Mcl-1 down-regulation
por: Bonnefond, Marie-Laure, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4c0bdncm3upjb8m78majri2783